S-1: Akari Therapeutics Registers Warrants for Resale

Akari Therapeutics filed an S-1 registration statement for the resale of 6.375 million ADSs by selling shareholders, stemming from recent warrant issuances.

Summary

• Akari Therapeutics, an oncology company focused on novel antibody-drug conjugates (ADCs), filed an S-1 registration statement for the resale of up to 12,750,000,000 ordinary shares, represented by 6,375,000 American Depositary Shares (ADSs).
• These ADSs are issuable upon the exercise of Series E, Series F, and Placement Agent Warrants issued in a private placement and concurrent registered direct offering in October 2025.
• The company will not receive any direct proceeds from the sale of these ADSs by the selling shareholders, but may receive up to $6,250,000 from warrant exercises if they are not exercised on a cashless basis.
• In October 2025, Akari raised approximately $2.5 million in gross proceeds from a registered direct offering and concurrent private placement, selling ADSs and accompanying warrants at a combined purchase price of $0.80 per ADS.
• The Series E and F Warrants have an exercise price of $0.98 per ADS, with terms of 5 years and 30 months respectively, commencing upon shareholder approval (expected by December 15, 2025).
• Akari's lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC, acquired through the November 2024 merger with Peak Bio.
• The company has suspended internal development of its legacy programs (nomacopan, PAS-nomacopan, PHP-303) and is seeking strategic partners for their external advancement.
• As of November 13, 2025, Akari had 71,479,461,523 ordinary shares outstanding, with its ADSs listed on the Nasdaq Capital Market under the symbol AKTX, closing at $0.529 on November 14, 2025.
• Pro forma financial information for the year ended December 31, 2024, shows a net loss of $(19,476,000) and total operating expenses of $25,669,000.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the explicit 'going concern' warnings from auditors for both Akari and its acquired subsidiary, significant ongoing operating losses, the preclinical stage of its lead product, and the substantial dilution risk posed by the warrant resale. While the company has a strategic focus on a promising area (ADCs), the financial instability and early stage of development present considerable challenges.

Positives

• The company is focused on developing next-generation antibody-drug conjugates (ADCs) with novel proprietary cancer-killing toxins, which it believes have the potential to transform cancer therapy.
• The lead product candidate, AKTX-101, is a preclinical stage Trop2-targeting ADC, targeting a prevalent cancer type.
• The company successfully completed a financing round in October 2025, raising approximately $2.5 million in gross proceeds, demonstrating some ability to attract institutional investors.

Negatives

• Akari Therapeutics has a history of operating losses and has not generated any product revenue, indicating a lack of commercialized products.
• The company's auditors, BDO USA, P.C., included an explanatory paragraph regarding Akari's ability to continue as a going concern in their report for the year ended December 31, 2024.
• Peak Bio, the acquired subsidiary, also had an auditor's report expressing substantial doubt about its ability to continue as a going concern.
• The company requires substantial additional capital to fund operations and cannot assure future revenues or operating profits.
• Material weaknesses in internal control over financial reporting have been identified.
• The company has suspended internal development of legacy programs, relying on external partnerships for their advancement, which introduces dependency and uncertainty.
• The offering involves the resale of a substantial number of ADSs (6,375,000), which could cause significant dilution and downward pressure on the stock price.

Risks

• An investment in the company's securities is speculative and involves a high degree of risk.
• The potential sale of 6,375,000 ADSs by selling shareholders could adversely affect the price of the ADSs on the Nasdaq Capital Market.
• The company has a history of operating losses and cannot assure future revenues or operating profits.
• Substantial additional capital is required to fund operations, and inability to obtain it will prevent successful development and commercialization.
• Material weaknesses in internal control over financial reporting have been identified.
• No clinical studies have been initiated for active pipeline programs, and commercialization, if ever, is years away.
• Preclinical studies or clinical trials may be prolonged or delayed, hindering regulatory approvals and commercialization.
• Serious adverse events, undesirable side effects, or unexpected properties of product candidates could lead to development discontinuation or refusal of approval.
• The proprietary ADC platform is based on novel, unproven technologies, exposing the company to unforeseen risks and making product development time/cost difficult to predict.
• Interim, initial, or preliminary preclinical/clinical results may change as more data become available.
• Clinical trials may be suspended, repeated, or terminated if not conducted according to requirements, if results are negative, or if trials are poorly designed.
• Employees, contractors, and partners may engage in misconduct or non-compliance with regulatory standards.
• The industry is highly competitive, and product candidates may become obsolete.
• Inability to establish sales, marketing, and distribution capabilities could prevent commercialization.
• Even if approved, product candidates may fail to achieve market acceptance by physicians, patients, or payors.
• Uncertain third-party payor coverage and reimbursement status for newly-approved products could limit marketability and revenue generation.
• Commercializing products in foreign markets subjects the company to additional regulatory burdens and risks.
• EU drug marketing and reimbursement regulations may materially affect the ability to market and receive coverage in EU Member States.
• Success depends on the ability to protect intellectual property and proprietary technologies.
• Reliance on third parties to conduct studies, trials, and manufacturing poses risks if they perform unsatisfactorily.
• Operating in a period of economic uncertainty and capital markets disruption, impacted by geopolitical instability and high inflation, could adversely affect business.
• Risks associated with conducting business internationally.
• Significant insider ownership could delay or prevent a change in corporate control or entrench management/board.
• Future sales and issuances of ordinary shares or ADSs, or rights to purchase them, could result in additional dilution.
• The company has in the past, and may in the future, fail to meet Nasdaq listing requirements, leading to delisting.
• The rights of shareholders may differ from those typically offered to shareholders of a U.S. corporation.
• Difficulty for U.S. investors to enforce foreign judgments against the company or its foreign directors/officers.

Future Outlook

The company anticipates requiring substantial additional capital to fund its operations and cannot assure future revenues or operating profits. It expects that successful development and eventual commercialization of potential therapies, if it ever occurs, will take a number of years. The company aims to establish AKTX-101 as a best-in-class Trop2-targeting ADC and intends to seek strategic partners for its legacy programs (nomacopan, PAS-nomacopan, PHP-303).

Management Comments

• "We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development."
• "We aim to establish AKTX-101 as a best-in-class Trop2-targeting ADC for the treatment of a variety of solid tumors."
• "Our ability to generate revenue sufficient to achieve profitability, if ever, will depend on the successful development and eventual commercialization of our potential therapies, which we expect, if it ever occurs, will take a number of years."

Industry Context

Akari Therapeutics operates in the highly competitive oncology and biotechnology sectors, specifically focusing on antibody-drug conjugates (ADCs). The company highlights its differentiated approach by focusing on novel payloads, contrasting with the industry's current reliance on two standard payload classes (microtubule inhibitors and DNA-damaging agents). This strategy aims to address limitations in existing ADC therapies, potentially offering improved cytotoxicity, immune response activation, and reduced tumor resistance. The shift from legacy programs to the ADC platform, following the Peak Bio acquisition, positions Akari within a rapidly evolving segment of cancer treatment, where innovation in targeting and payload delivery is crucial for competitive advantage.

Comparison to Industry Standards

• The company's focus on novel payloads for ADCs differentiates it from over 90% of ADCs in late-stage clinical development, which utilize payloads from two standard classes (microtubule inhibitors or DNA-damaging agents). This suggests a potential for a unique market position if successful, but also carries higher development risk due to unproven technology.
• The company's lead candidate, AKTX-101, is a preclinical stage Trop2-targeting ADC. Several companies, such as Gilead Sciences (Trodelvy/sacituzumab govitecan) and Daiichi Sankyo/AstraZeneca (Enhertu/trastuzumab deruxtecan), have approved or advanced ADCs targeting various antigens, including Trop2. Akari aims for AKTX-101 to be 'best-in-class,' implying a direct competitive stance against established and emerging players in the ADC space, which is a high bar given its preclinical stage.

Corporate Governance

Legal Proceedings

• The company is incorporated under the laws of England and Wales, and several directors/officers reside outside the U.S., making it difficult for U.S. investors to serve legal process or enforce U.S. judgments in England due to lack of a reciprocal treaty.

Related Party Transactions

• Dr. Ray Prudo (Chairman) and Ms. Rachelle Jacques (President & CEO) participated in the September 2023 Private Placement, purchasing ADSs and pre-funded warrants.
• Dr. Ray Prudo (Chairman) and Dr. Samir Patel (Director) participated in the December 2023 Private Placement, purchasing ADSs.
• Dr. Ray Prudo and Dr. Samir Patel participated in the November 2024 Private Placement, purchasing ADSs and Series D Warrants.
• Dr. Hoyoung Huh (Chairman) agreed to purchase $1.0 million of units in the March 2025 Private Placement by canceling and extinguishing $1.0 million of notes previously issued to him by Peak Bio.
• Dr. Hoyoung Huh (Chairman) purchased an August 2025 Note with a principal amount of $1,250,000 for a purchase price of $1,000,000, satisfied partly by cash and partly by cancellation of $837,433 in outstanding principal and accrued interest under a senior secured promissory note from Peak Bio.
• Other directors also participated in the August 2025 Note Offering.

Stakeholder Impact

• **Shareholders:** Face significant potential dilution from the resale of warrants and future capital raises. The 'going concern' warning indicates substantial risk to their investment. Shareholder approval is required for warrant exercises, giving them a direct say in a key financing event.
• **Employees:** The company's focus shift to ADCs and suspension of legacy programs may impact employees involved in those older programs. The need for substantial capital could affect job security if not secured.
• **Customers (future):** The development of novel ADCs could eventually offer new treatment options for cancer patients, but this is a long-term prospect given the preclinical stage.
• **Creditors:** The 'going concern' warning and history of operating losses indicate elevated risk for creditors. The August 2025 Note Offering involved unsecured promissory notes, placing those creditors at higher risk.
• **Strategic Partners:** The company is actively seeking strategic partners for its legacy programs, indicating potential opportunities for collaboration and external development.

Next Steps

• Hold a special meeting of shareholders on or before December 15, 2025, to obtain approval for the issuance of ADSs issuable upon exercise of the Common Warrants.
• Advance the lead product candidate, AKTX-101, through preclinical development.
• Seek strategic partners to advance the legacy programs (nomacopan, PAS-nomacopan, PHP-303) externally.
• Continue research and development activities for the ADC Platform.
• Secure substantial additional capital to fund ongoing operations and product development.

Key Dates

Recommendation

The filing reveals critical financial distress, including explicit 'going concern' warnings from auditors for both Akari and its recently acquired subsidiary, Peak Bio. The company has a history of significant operating losses and no product revenue, relying heavily on capital raises. The current offering is for the resale of a substantial number of shares underlying warrants, which will lead to significant dilution for existing shareholders and likely downward pressure on the stock price. While the company's focus on novel ADC technology is strategically interesting, its lead candidate is still in preclinical stages, implying a long, costly, and high-risk development pathway. Given the severe financial instability, high dilution risk, and early-stage pipeline, a seasoned investor would likely view this as a 'strong sell' due to the significant downside risk and uncertainty regarding the company's long-term viability.

Keywords

Akari Therapeutics, AKTX, S-1 filing, SEC filing, biotechnology, oncology, antibody-drug conjugates, ADCs, cancer therapy, warrants, private placement, resale offering, Nasdaq Capital Market, AKTX-101, Trop2, preclinical, going concern, dilution, capital raise, pharmaceuticals